Moleculin Biotech

$0.761
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0191 (-2.42%) Today
-$0.0098 (-1.27%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MBRX and other stocks, options, and ETFs commission-free!

About MBRX

Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Read More Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX. The listed name for MBRX is Moleculin Biotech, Inc. Common Stock.

Employees
16
Headquarters
Houston, Texas
Founded
2015
Market Cap
47.56M
Price-Earnings Ratio
Dividend Yield
Average Volume
429.88K
High Today
$0.7935
Low Today
$0.766
Open Price
$0.768
Volume
525.43K
52 Week High
$1.97
52 Week Low
$0.323

Collections

MBRX Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 12, Pre-Market

You May Also Like